公开(公告)号：EP1409477B1

公开(公告)日：2008-09-17

申请号：EP02753161.5

申请日：2002-07-23

申请人： Richter Gedeon NYRT

发明人： DOMANY, György ,  HORVATH, Csilla ,  FARKAS, Sándor ,  BARTANE SZALAI, Gizella ,  NAGY, József ,  KOLOK, Sándor ,  BOZO, Eva ,  BORZA, István ,  VAGO, István ,  BIELIK, Attila ,  IGNACZNE SZENDREI, Györgyi ,  KESERÜ, György

IPC分类号： C07D401/12 ,  C07D413/12 ,  C07D295/185 ,  C07D407/12 ,  C07D417/12 ,  C07D451/02 ,  A61K31/445 ,  A61P25/28

CPC分类号： C07D211/14 ,  C07D211/16 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention relates to new carboxylic acid amide derivatives of formula (I), wherein U, V, W, X, Y, Z, n and m are as defined as in Claim 1. A further object of the invention are the processes for producing of carboxylic acid amide compounds of formula (I), and the pharmaceutical manufacture of medicaments containing these compounds, as well as the process of treatments with these compounds, which means administering to a mammal to be treated including human - effective amount/amounts of compounds of formula (I) of the present invention as such or as medicament. The new carboxylic acid amide derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.

公开(公告)号：EP1438302B1

公开(公告)日：2012-05-30

申请号：EP02765129.8

申请日：2002-09-25

申请人： Richter Gedeon Nyrt.

发明人： GALAMBOS, János ,  NOGRADI, Katalin ,  AGAINE CSONGOR, Eva ,  KESERU, György, Miklos ,  VAGO, István ,  DOMANY, György ,  KISS, Béla ,  GYERTYAN, István ,  LASZLOVSZKY, István ,  LASZY, Judit

IPC分类号： C07D211/14 ,  C07D211/18 ,  C07D211/44 ,  C07D295/04 ,  C07D295/12

CPC分类号： C07D295/135 ,  C07D211/14 ,  C07D211/18 ,  C07D211/28 ,  C07D211/44 ,  C07D211/46 ,  C07D211/58 ,  C07D213/71 ,  C07D295/04 ,  C07D295/12

摘要： The present invention relates to new D3 dopamine receptor subtype selectice ligands of formula (I) to pharmacological compositions containing the same and to their us in therapy and/or prevention of psychoses (e.g. schizophrenia, schizo-affective disorders, etc), drug (e.g. alcohol, cocaine and nicotine, opioids etc.) abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, amnesia, eating disorders (e.g. bulimia nervosa, etc.), attention deficit disorders, hyperactivity disorders in children, psychotic depression, mania, paranoid and delusional disorders, dyskinetic disorders (e.g. Parkinson's diseases, neuroleptic induced Parkinson's desases, tardive dyskinesias) anxiety, sexual dysfunction, sleep disorders, emesis, aggression, autism, pain ophthalmological diseases (e.g. glaucoma etc.).